A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Public ClinicalTrials.gov record NCT07060807. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estrogen or progesterone (hormones) which help the cancer to grow and spread * HER2 negative (HER2-) means the cancer cells have a low amount of a protein called HER2 * Unresectable locally advanced means the cancer cannot be completely removed by surgery and has spread into nearby tissue or muscles * Metastatic means the cancer has spread to other parts of the body Treatment for this type of breast cancer usually includes endocrine therapy (ET) and sometimes a second treatment. The main goal of this study is to learn if people who receive patritumab deruxtecan (also known as HER3-DXd and MK-1022) live longer overall or without the cancer growing/spreading, compared to people who receive chemotherapy or a different drug called trastuzumab deruxtecan.
Study identification
- NCT ID
- NCT07060807
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,000 participants
Conditions and interventions
Conditions
Interventions
- Patritumab deruxtecan Biological
- Paclitaxel Drug
- Nab-paclitaxel Drug
- Capecitabine Drug
- Liposomal doxorubicin Drug
- Trastuzumab deruxtecan Biological
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 20, 2025
- Primary completion
- Jul 13, 2033
- Completion
- Jul 13, 2033
- Last update posted
- Aug 27, 2026
2025 – 2033
United States locations
- U.S. sites
- 34
- U.S. states
- 18
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center (SCC) ( Site 8000) | Daphne | Alabama | 36526 | Recruiting |
| The University of Arizona Cancer Center - North Campus ( Site 0055) | Tucson | Arizona | 85719 | Recruiting |
| Los Angeles Hematology Oncology Medical Group ( Site 0026) | Los Angeles | California | 90017 | Recruiting |
| Hoag Memorial Hospital Presbyterian ( Site 0025) | Newport Beach | California | 92663 | Recruiting |
| St. Marys Hospital and Regional Medical Center-SCL Health Cancer Centers of Colorado ( Site 0021) | Grand Junction | Colorado | 81501 | Recruiting |
| Medical Oncology Hematology Consultants (MOHC) ( Site 8002) | Newark | Delaware | 19713 | Recruiting |
| AdventHealth Medical Group Oncology and Hematology at Altamonte ( Site 0024) | Altamonte Springs | Florida | 32701 | Recruiting |
| Comprehensive Hematology Oncology ( Site 0060) | St. Petersburg | Florida | 33709 | Recruiting |
| Baptist Health Lexington ( Site 0050) | Lexington | Kentucky | 40503 | Recruiting |
| Baptist Health Hamburg ( Site 0071) | Lexington | Kentucky | 40509 | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001) | Hackensack | New Jersey | 07601 | Recruiting |
| Rutgers Cancer Institute of New Jersey ( Site 0033) | New Brunswick | New Jersey | 08903 | Recruiting |
| Presbyterian Kaseman Hospital ( Site 0072) | Albuquerque | New Mexico | 87110 | Recruiting |
| University of New Mexico Comprehensive Cancer Center ( Site 0047) | Albuquerque | New Mexico | 87131 | Recruiting |
| Presbyterian Rust Jorgensen Cancer ( Site 0073) | Rio Rancho | New Mexico | 87124 | Recruiting |
| Queens Hospital Cancer Center ( Site 0011) | Jamaica | New York | 11432 | Recruiting |
| Optum Medical Care, PC ( Site 0009) | Westbury | New York | 11590 | Recruiting |
| Novant Health Cancer Institute ( Site 0019) | Charlotte | North Carolina | 28204 | Recruiting |
| Novant Health Oncology Specialists ( Site 0074) | Winston-Salem | North Carolina | 27103 | Recruiting |
| TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0020) | Cincinnati | Ohio | 45220 | Recruiting |
| University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0058) | Pittsburgh | Pennsylvania | 15213 | Recruiting |
| Cancer Care Associates Of York ( Site 0063) | York | Pennsylvania | 17403 | Recruiting |
| SCRI Oncology Partners ( Site 7000) | Nashville | Tennessee | 37203 | Recruiting |
| Tennessee Oncology ( Site 0068) | Nashville | Tennessee | 37203 | Recruiting |
| Texas Oncology - DFW ( Site 8003) | Dallas | Texas | 75246 | Recruiting |
| JPS Health Network ( Site 0067) | Fort Worth | Texas | 76104 | Recruiting |
| Texas Oncology - Gulf Coast ( Site 8006) | Houston | Texas | 77024 | Recruiting |
| Oncology Consultants P.A. ( Site 0061) | Houston | Texas | 77030 | Recruiting |
| Texas Oncology - Central/South Texas ( Site 8005) | McAllen | Texas | 78503 | Recruiting |
| Mays Cancer Center ( Site 0049) | San Antonio | Texas | 78229 | Recruiting |
| Virginia Oncology Associates (VOA) ( Site 8001) | Norfolk | Virginia | 23502 | Recruiting |
| Shenandoah Oncology ( Site 8004) | Winchester | Virginia | 22601 | Recruiting |
| Northwest Medical Specialties, PLLC ( Site 0062) | Tacoma | Washington | 98405 | Recruiting |
| Circuit Clinical/SSM Health Dean Medical Group ( Site 0039) | Madison | Wisconsin | 53715 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 165 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07060807, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07060807 live on ClinicalTrials.gov.